NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Anbio Biotechnology
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$3.27+0.14 (+4.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 22.2
- Dividend yield
- –
Fundamental chart
Pick a measure to chart its full history
$8.65MFY2025, -28.4% a year since FY2022